65,437 trials
Relapsed or Refractory Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013 — 8.1; NA months — p=<0.0001
Allergic Rhinitis
Primary: Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) Over The First 6 Weeks Of Treatment In…
Gastric or Duodenal Ulcers
Primary: Frequency of Adverse Drug Reactions — 1; 1; 1; 1 participants
Breast Cancer
Primary: Disease Free Survival — NA; NA Months — p=0.3150
Asian Nose Enhancement
Primary: Percentage of Participants With a ≥ 1 Grade Improvement on the Assessment of Aesthetic Improvement Scale (AAIS) as Assessed by the Central Evaluating Physician at Day…
Peripheral Arterial Disease · Claudication · Critical Limb Ischemia
Primary: Primary Patency Rate (in Patients Treated for Claudication RCC 1-3) — 81.6 percentage of lesions by Kaplan Meier
Chronic Periodontitis
Primary: Clinical Attachment Level — 6.42; 6.15; 3.52; 3.6 mm
Major Depressive Disorder With Mixed Features
Primary: Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores — -20.5; -13.0 units on a scale — p=<0.0001
Healthy
Primary: Percentage of Subjects With Bactericidal Titers, BCA ≥1:4, 30 Days After the Third Immunization — 11; 11; 78; 87 Percentage of subjects
Fibromyalgia
Primary: Numeric Pain Rating System (NPRS) — 7.29; 4.72; 3.95; 3.83 units on a scale
Primary Hypercholesterolemia · Mixed Dyslipidemia
Primary: Percentage of Participants With Full Administration of Evolocumab at Both Weeks 2 and 4 — 96.0; 89.2 percentage of participants
Salt-sensitive Hypertension
Primary: Cumulative Sodium Excretion (Natriuresis) at Day 1 — 61.26; 37.13; 188.87; 138.92 mmol
Burns
Primary: Healing Time for Donor Site Wounds — 9.4; 12.4 days
Bronchiectasis · Lung Disease · Respiratory Diseases
Primary: Ratio of Absolute Neutrophil Cell Count in Sputum at End of Treatment Compared to Baseline — 0.31; 1.00 ratio — p=0.004
Major Depressive Disorder (MDD)
Primary: Mean Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -12.8; -18.4; -19.5; -19.2 Units on a scale — p=<0.0001